Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Adagio Medical Holdings (ADGM) Research & Development (2023 - 2025)

Adagio Medical Holdings (ADGM) has disclosed Research & Development for 3 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.6 million for FY2025, N/A changed from the prior year.
  • Research & Development for Q4 2025 was $2.2 million at Adagio Medical Holdings, down from $2.8 million in the prior quarter.
  • The five-year high for Research & Development was $4.4 million in Q3 2023, with the low at $1.2 million in Q3 2024.
  • Average Research & Development over 3 years is $2.7 million, with a median of $2.8 million recorded in 2025.
  • The sharpest move saw Research & Development plummeted 72.45% in 2024, then skyrocketed 127.94% in 2025.
  • Over 3 years, Research & Development stood at $1.8 million in 2023, then crashed by 31.4% to $1.2 million in 2024, then surged by 83.65% to $2.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.2 million, $2.8 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.